Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study

Robert C. Stassen, Evalyn E.A.P. Mulder, Antien L. Mooyaart, Anne Brecht Francken, Jos van der Hage, Maureen J.B. Aarts, Astrid A.M. van der Veldt, Cornelis Verhoef, Dirk J. Grünhagen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Sentinel lymph node biopsy (SLNB) is recommended for patients with >pT1b cutaneous melanoma, and should be considered and discussed with patients diagnosed with pT1b cutaneous melanoma for the purpose of staging, prognostication and determining eligibility for adjuvant therapy. Previously, the clinicopathologic and gene expression profile (CP-GEP, Merlin Assay®) model was developed to identify patients who can forgo SLNB because of a low risk for sentinel node metastasis. The aim of this study was to evaluate the clinical use and implementation of the CP-GEP model in a prospective multicenter study in the Netherlands. Both test performance and feasibility for clinical implementation were assessed in 260 patients with T1-T4 melanoma. The CP-GEP model demonstrated an overall negative predictive value of 96.7% and positive predictive value of 23.7%, with a potential SLNB reduction rate of 42.2% in patients with T1-T3 melanoma. With a median time of 16 days from initiation to return of test results, there was sufficient time left before the SLNB was performed. Based on these outcomes, the model may support clinical decision-making to identify patients who can forgo SLNB in clinical practice.
Original languageEnglish
Article number107249
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume49
Issue number12
DOIs
Publication statusPublished - 1 Dec 2023

Keywords

  • Gene-expression profiling
  • Melanoma
  • Prospective
  • Sentinel node
  • Surgery

Fingerprint

Dive into the research topics of 'Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study'. Together they form a unique fingerprint.

Cite this